Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.79 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.65 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | CCR3 | P51677 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3963041 | 1.00 | SIGMAR1 (0.79) | SIGMAR1SLC6A3SLC6A4HTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL2195558 | 0.98 | SIGMAR1 (0.77) | SIGMAR1SLC6A3SLC6A4HTR1ADRD2 | |
| SCHEMBL29393817 | 0.98 | SIGMAR1 (0.77) | SIGMAR1SLC6A3SLC6A4HTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL16739273 | 0.98 | SIGMAR1 (0.77) | SIGMAR1SLC6A3SLC6A4HTR1ADRD2 | |
| SCHEMBL8668531 | 0.93 | SLC6A3 (0.70) | SIGMAR1SLC6A3SLC6A4HTR1ADRD2 | |
| Alcohol SCHEMBL27791355 | 0.91 | SIGMAR1 (0.68) | SIGMAR1SLC6A3SLC6A4HTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL7983455 | 0.91 | SLC6A3 (0.68) | SIGMAR1SLC6A3SLC6A4HTR1ADRD2 | |
| Acetic Acid SCHEMBL27373593 | 0.90 | SIGMAR1 (0.66) | SIGMAR1SLC6A3SLC6A4HTR1ADRD2 | |
| SCHEMBL10677264 | 0.89 | SIGMAR1 (1.00) | SIGMAR1CCR3LTA4H | |
| SCHEMBL457139 | 0.89 | SIGMAR1 (1.00) | SIGMAR1CCR3LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1029 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | claimed |
| CN-114736236-B | Polynuclear annular organotin oxygen sulfur cluster compound and preparation method and application thereof | 中国科学院福建物质结构研究所 | 2023-09-29 | — | — | CN | claimed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | claimed |
| CN-114736236-A | Polynuclear cyclic organotin-oxygen-sulfur cluster compound and preparation method and application thereof | 中国科学院福建物质结构研究所 | 2022-07-12 | — | — | CN | claimed |
| CN-104046246-B | The chemical-mechanical planarization of tungsten-containing substrate | 气体产品与化学公司 | 2016-06-15 | — | — | CN | claimed |
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | claimed |
| US-8445484-B2 | Bicyclic peptidomimetic inhibitors of aspartyl-proteases for the treatment of infectious diseases | ISTITUTO SUPERIORE DI SANITA' (IT) | 2013-05-21 | — | — | US | claimed |
| EP-2118110-B1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-07-25 | — | — | EP | claimed |
| CN-1088923-A | Piperazinyl or piperamylcyclohexanol, preparation and use thereof | BRISTOL MYERS SQUIBB CO (US) | 1994-07-06 | — | — | CN | claimed |
| EP-0507863-A4 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | — | 1993-07-07 | — | — | EP | claimed |
| EP-0507863-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1992-10-14 | — | — | EP | claimed |
| EP-0427765-A1 | ALKOXY-4(1H)-PYRIDONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USE AS DRUGS | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1991-05-22 | — | — | EP | claimed |
| EP-0385043-A1 | New derivatives of 4-substituted piperazines | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (FAES) (ES) | 1990-09-05 | — | — | EP | claimed |
| WO-1990001477-A1 | ALKOXY-4(1H)-PYRIDONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USE AS DRUGS | Gödecke Aktiengesellschaft (DE) | 1990-02-22 | — | — | WO | claimed |
| EP-0354495-A1 | Alkoxy-4(1H)-pyridone derivatives, process for their preparation and their pharmaceutical use | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1990-02-14 | — | — | EP | claimed |
| US-4818748-A | HYPOTENSIVE AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-04-04 | — | — | US | claimed |
| EP-0236874-A2 | Renin inhibitors, their production and use, as well as derivatives of amino acids and amino aldehydes | BAYER AG (DE) | 1987-09-16 | — | — | EP | claimed |
| EP-0232089-A2 | Quinone amides, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1987-08-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | SIGMAR1 2433/4885SLC6A3 3280/4885SLC6A4 3594/4885 |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | HBZ, ZFX, WIZ | SIGMAR1 2433/4885SLC6A3 3280/4885SLC6A4 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.